Preemptively treating patients most at risk of progression to myeloma

Bookmark and Share
Published: 1 Nov 2016
Views: 2368
Prof Maria-Victoria Mateos - University Hospital of Salamanca, Salamanca, Spain

Prof Mateos talks to ecancertv at ICMM 2016 about the use of monoclonal gammopathy in early-stage pre-malignant disorders.

Unfortunately, she says, certain patients will see their disorder evolve into active myeloma disease.

She says it is important to predict better which patients are most at risk so they can be treated preemptively, possibly with lenalidomide and dexamethasone.

For more on this, watch the interview with Dr Van De Donk.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content